X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DNA plasmids
Therapeutic Area: Neurology Product Name: CG01
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CombiGene AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 13, 2020
Details:
Cobra Biologics has successfully produced and supplied further two DNA plasmids for the production of CombiGene AB’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CG01
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
Details:
Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
